NEW YORK (TheStreet) -- UBS upgraded Allergan (AGN - Get Report) to "buy" from "neutral" and set a $200 price target. The firm said the company plans to see more sales growth while they consider a deal with Valeant (VRX).
Leerink Swann also increased its price target on Allergan to $184, increased its estimates and set a "market perform" rating. The firm said the company is aggressively cutting costs.
The stock closed at $171.14 on Monday.